The efficacy and safety of monoclonal antibody therapies for interstitial cystitis/bladder pain syndrome: A meta‐analysis of randomized controlled trials

Author:

Cao Zhi‐Gang1,Li Fu‐Dong1,Zhang Chun‐Lei1,Luo Guo‐Xiong1,Chang De‐Hui1ORCID

Affiliation:

1. Department of Urology The 940th Hospital of PLA Joint Logistic Support Force Lanzhou Gansu China

Abstract

AbstractObjectivesThis study aimed to assess the efficacy and safety of monoclonal antibody therapies (MATs) for interstitial cystitis/bladder pain syndrome (IC/BPS).MethodsA systematic search was conducted across databases including PubMed, Embase, clinicalTrial.gov, and the Cochrane Library Central Register of Controlled Trials. Randomized controlled trials (RCTs) comparing MATs versus placebo were included. Primary outcomes comprised the Global Response Assessment (GRA) scale and the O'Leary‐Sant Interstitial Cystitis Symptom Index (ICSI). Additional analyses encompassed mean daily frequency of voids, the O'Leary‐Sant Interstitial Cystitis Problem Index, pain scores, and complications. Statistical analyses were performed using Review Manager 5.3.ResultsFive high‐quality RCTs, comprising 263 patients with IC/BPS, were ultimately selected. MATs were generally effective in treating IC/BPS. Patients receiving MATs exhibited a higher satisfaction rate (odds ratio [OR]: 2.7, confidence interval [CI]: 1.31–5.58, p = 0.007) and lower ICSI scores (mean difference [MD]: −1.44, CI: −2.36 to −0.52, p = 0.002). Moreover, MAT recipients experienced reduced pain (MD: −0.53, CI: −0.79 to −0.26, p < 0.0001) and decreased frequency of urination (MD: −1.91, CI: −2.55 to −1.27, p < 0.00001). Importantly, there were no disparities regarding complication incidence in the MAT and control groups.ConclusionsThe current findings indicate that MATs are effective and safe for treating IC/BPS. Nonetheless, future RCTs with larger sample sizes and long‐term follow‐up are warranted.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3